BACE1-targeted small molecule inhibitors have advanced to phase 3 clinical trials for AD, where they efficiently lowered Aβ in brain and cerebrospinal fluid (CSF) of AD patients and individuals at high risk for AD (2). The gene discussed is BACE1; the disease is Alzheimer disease.